CNS Pharmaceuticals appoints Bettina Cockroft, M.D., M.B.A. to Board of Directors

CNS Pharmaceuticals, Inc.

Appointed Bettina Cockroft as independent director effective May 3, 2023; no committee assignments at this time.
Granted ten-year option for 8,300 shares at $1.67, vesting monthly over 36 months.
Cockroft is SVP/CMO of Sangamo Therapeutics, with over 30 years biopharma experience.
Standard non-employee director compensation applies, as described in prior SEC filings.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bettina M. Cockroft

Independent Director

CNSP · CNS Pharmaceuticals, Inc.

Effective: 2023-05-03
Filed: May 8, 2023, 7:59 PM ET

On May 3, 2023, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., M.B.A as an independent member of the Company’s Board of Directors effective on such date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bettina M. Cockroft was appointed as Independent Director at CNS Pharmaceuticals, Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

On May 3, 2023, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., M.B.A as an independent member of the Company’s Board of Directors effective on such date.

View on SEC.gov

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-003010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.